André N. Vis - Concepedia

Author

André N. Vis

Amsterdam University Medical Centers ORCID

Also Known As

A Vis, A. N. Vis, A. Vis, A.N. Vis, ANDRÉ N. VIS, Andre N Vis, Andre N. Vis, Andre Vis, André N. Vis, Andrè N. Vis

318

Publications

Citations

H-Index

Concepts

All Affiliations

Amsterdam University Medical Centers The Netherlands Cancer Institute Amsterdam UMC Location Vrije Universiteit Amsterdam Erasmus MC Erasmus University Rotterdam

About

André N. Vis is an author at Amsterdam University Medical Centers specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	32	2.3K
2	Health Sciences	6	6	173
3	Public Health	3	3	156
4	Engineering	2	2	85
5	Social Sciences	2	2	43

André N. Vis

Publications

Citations

H-Index

Page 1

	Year	Citations
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, European Urology UrologyRadiation MedicineRadiation TherapyMedicineHorrad Trial	2018	554
PROSTATE CANCER DETECTION AT LOW PROSTATE SPECIFIC ANTIGEN Fritz H. Schröder, Ingrid van der Cruijsen‐Koeter, Harry J. de Koning, The Journal of Urology	2000	323
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome Bas W.G. van Rhijn, André N. Vis, Theodorus van der Kwast, Journal of Clinical Oncology	2003	319
<b> <i>FGFR3</i> </b> and <b> <i>P53</i> </b> Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma Bas W.G. van Rhijn, Theodorus van der Kwast, André N. Vis, Cancer Research Tumor BiologyP53 AlterationsUrologyUrothelial Cell CarcinomaGenitourinary Cancer	2004	219
Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, André N. Vis, European Urology UrologyCancer RiskUrologic Cancer EpidemiologyGenitourinary CancerMedicine	2010	190
The Actual Value of the Surgical Margin Status as a Predictor of Disease Progression in Men with Early Prostate Cancer André N. Vis, Fritz H. Schröder, Theodorus van der Kwast European Urology Early Prostate CancerUrologySurgical OncologyActual ValueGenitourinary Cancer	2006	142
Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles Danijela Koppers‐Lalic, Michael Hackenberg, Renée de Menezes, Oncotarget	2016	136
Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer Matthijs C. F. Cysouw, B.H.E. Jansen, Tim van de Brug, European Journal of Nuclear Medicine and Molecular Imaging	2020	134
Prostate-specific antigen-based early detection of prostate cancer—validation of screening without rectal examination Fritz H. Schröder, Monique Roobol-Bouts, André N. Vis, Urology Prostate Cancer—validationUrologyGenitourinary CancerCancer DetectionCancer Screening	2001	124
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients Judith Bosschieter, Jakko A. Nieuwenhuijzen, Tessa van Ginkel, European Urology Urological ResearchUrologySurgical OncologyGenitourinary CancerMitomycin C	2017	122

Page 1